🩸 Ebola Vaccine Tracker Dashboard

Tracking Ebola vaccine development and deployment for outbreak response. Ebola virus disease (EVD) causes severe hemorrhagic fever with case fatality rates up to 90%. UPDATED JULY 2026 — Bundibugyo virus PHEIC: On May 17, 2026, WHO declared the Ebola outbreak caused by Bundibugyo virus (BDBV) in the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern. Africa CDC declared it a Public Health Emergency of Continental Security on May 18. Current evidence suggests this is a novel spillover event from the animal reservoir. Only Merck's Ervebo (rVSV-ZEBOV) remains a licensed Ebola vaccine — but it is indicated for Zaire ebolavirus only, not Bundibugyo, and WHO/SAGE recommends it not be used outside carefully designed research settings in the current outbreak, as cross-protection evidence is limited. The J&J two-dose Zabdeno/Mvabea regimen had its European Commission marketing authorisation withdrawn in May 2026. IAVI is in discussions to supply investigational Sudan virus vaccine (same cAd3 platform as Sabin's) for Bundibugyo research studies. The UNICEF-controlled international Ebola vaccine stockpile holds 500,000 Ervebo doses for Zaire ebolavirus outbreaks. Ebola vaccine information. This tracker monitors licensed vaccines and next-generation candidates for improved outbreak response.